Sakakura Kenichi, Kubo Norifumi, Ako Junya, Fujiwara Naoki, Funayama Hiroshi, Ikeda Nahoko, Nakamura Tomohiro, Sugawara Yoshitaka, Yasu Takanori, Kawakami Masanobu, Momomura Shin-ichi
Division of Cardiovascular Medicine, Department of Integrated Medicine I, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Am J Hypertens. 2009 Apr;22(4):371-7. doi: 10.1038/ajh.2009.5. Epub 2009 Feb 5.
Type B acute aortic dissection (AAD) carries a high short- and midterm mortality rate; however, knowledge related to long-term outcome is largely incomplete. The objective of this study was to identify long-term predictors including antihypertensive medications in type B AAD.
We conducted a clinical follow-up study on 202 type B AAD patients. Univariate and multivariate Cox regression analyses were performed to identify predictors of mortality.
There were 44 postdischarge deaths in 202 consecutive type B AAD patients with a median follow-up of 55 months. In univariate Cox regression analysis, age (10 year incremental: hazard ratio (HR) 1.82, 95% confidence interval (CI) 1.35-2.46, P < 0.0001), previous myocardial infarction or angina pectoris (HR 3.93, 95% CI 1.72-8.99, P = 0.001), and impaired renal function (HR 4.90, 95% CI 2.48-9.65, P < 0.0001) were predictors of death. Calcium channel blockers (CCBs), beta-blockers, and angiotensin-converting enzyme (ACE) inhibitors as antihypertensive medications at discharge were predictors of increased survival. In multivariate Cox regression analysis, CCBs were a significant predictor of increased survival (vs. no antihypertensive medication at discharge: HR 0.38, 95% CI 0.15-0.97, P = 0.04). Impaired renal function was a significant predictor of death (HR 3.41, 95% CI 1.58-7.33, P = 0.002). No antihypertensive medication at discharge group was significantly associated with increased mortality (vs. 1 class of antihypertensive medication: HR 9.51, 95% CI 1.85-48.79, P = 0.007).
Impaired renal function was a predictor for adverse outcome in patients with type B AAD. The use of CCBs as antihypertensive medication at discharge was associated with increased survival.
B型急性主动脉夹层(AAD)的短期和中期死亡率很高;然而,关于长期预后的知识在很大程度上并不完整。本研究的目的是确定B型AAD的长期预测因素,包括抗高血压药物。
我们对202例B型AAD患者进行了临床随访研究。进行单因素和多因素Cox回归分析以确定死亡率的预测因素。
202例连续的B型AAD患者中,有44例出院后死亡,中位随访时间为55个月。在单因素Cox回归分析中,年龄(每增加10岁:风险比(HR)1.82,95%置信区间(CI)1.35 - 2.46,P < 0.0001)、既往心肌梗死或心绞痛(HR 3.93,95% CI 1.72 - 8.99,P = 0.001)以及肾功能受损(HR 4.90,95% CI 2.48 - 9.65,P < 0.0001)是死亡的预测因素。出院时使用钙通道阻滞剂(CCB)、β受体阻滞剂和血管紧张素转换酶(ACE)抑制剂作为抗高血压药物是生存增加的预测因素。在多因素Cox回归分析中,CCB是生存增加的显著预测因素(与出院时未使用抗高血压药物相比:HR 0.38,95% CI 0.15 - 0.97,P = 0.04)。肾功能受损是死亡的显著预测因素(HR 3.41,95% CI 1.58 - 7.33,P = 0.002)。出院时未使用抗高血压药物组与死亡率增加显著相关(与使用1类抗高血压药物相比:HR 9.51,95% CI 1.85 - 48.79,P = 0.007)。
肾功能受损是B型AAD患者不良预后的预测因素。出院时使用CCB作为抗高血压药物与生存增加相关。